{"id":842290,"date":"2025-04-25T16:19:04","date_gmt":"2025-04-25T20:19:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/"},"modified":"2025-04-25T16:19:04","modified_gmt":"2025-04-25T20:19:04","slug":"aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/","title":{"rendered":"AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">IRVINE, Calif., April  25, 2025  (GLOBE NEWSWIRE) &#8212; AEON Biopharma, Inc. (\u201cAEON\u201d or the \u201cCompany\u201d) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today it has received notification (the \u201cAcceptance Letter\u201d) from the NYSE American LLC (\u201cNYSE American\u201d) that NYSE American has accepted the Company&#8217;s previously submitted plan (the \u201cPlan\u201d) to regain compliance with NYSE American&#8217;s continued listing standards set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide (the \u201cCompany Guide\u201d) relating to minimum market capitalization and stockholders&#8217; equity.<\/p>\n<p align=\"justify\">In the Acceptance Letter, NYSE American granted the Company until August 3, 2026 (the \u201cPlan Period\u201d) to regain compliance with the continued listing standards. During the Plan Period, the Company will be subject to periodic review by NYSE American on its progress with the goals and initiatives outlined in the Plan. The Company intends to take all reasonable measures available to regain compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide during the Plan Period. If the Company does not regain compliance with the NYSE American listing standards by August 3, 2026, or if the Company does not make sufficient progress consistent with the Plan during the Plan Period, then NYSE American may initiate delisting proceedings.<\/p>\n<p>\n        <strong>About AEON Biopharma<\/strong>\n      <\/p>\n<p align=\"justify\">AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RkkJ36KZ3wmdsNb3TWGDVi9sSaDjX-t8gJvorA_csYI9gkQUYIOTwX2W3NPdG2XIawzI_-5uPCHJ8nopMcBBYULzEZtB9esdFxkjBu67IoXn-IL7ctdfLSfb_OEs2XzT3h7phFwSkQhN_HjqBseNa0Hdi1IVIJATp89bXNl3mLf1C5RpqvLH3opKEJSxTyhsBHM_sHR80T1LooXMZ0ZcmassolYoNppOf7IGWYbfWXKguiRCK5pg2H1q2WkBCRnS8XcTmzn75lkrJ2F3HJlnUOYTnAI047TP8Cg3tODUiuG4rKbijGgPfgQnbX7S-zzWe_OQsOruVQhbhmY9UY3ud9sjKjBAgaKuzhlFUTNmzno=\" rel=\"nofollow\" target=\"_blank\">www.aeonbiopharma.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p align=\"justify\">Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or AEON\u2019s future financial or operating performance. For example, statements regarding the Company\u2019s ability to execute on the Plan and regain compliance with the continued listing standards are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as \u201cplan\u201d, \u201cpossible\u201d, \u201cforecast\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cwill\u201d, \u201cestimate\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201cpredict\u201d, \u201cpotential\u201d, \u201ccontinue\u201d or \u201ccould\u201d, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.<\/p>\n<p align=\"justify\">These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by AEON and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against AEON or others; (ii) AEON\u2019s future capital requirements; (iii) AEON\u2019s ability to raise financing in the future; (iv) AEON\u2019s ability to maintain the cash balance required to work through our Biosimilar BPD Type 2a meeting with the FDA; (v) AEON\u2019s ability to continue to meet continued stock exchange listing standards; (vi) the possibility that AEON may be adversely affected by other economic, business, regulatory, and\/or competitive factors; (vii) AEON\u2019s ability to progress along a 351(k) biosimiliar pathway to allow ABP-450 to be approved as a biosimilar to BOTOX under a single FDA approval; (viii) the outcomes from any meetings or discussions with regulatory authorities; (ix) AEON\u2019s ability to execute on the Plan and regain compliance with the continued listing standards set forth in the Company Guide during the Plan Period; and (x) other risks and uncertainties set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s filings with the Securities and Exchange Commission (the \u201cSEC\u201d), which are available on the SEC\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=24jJEK0xQV_uZyCMcEyytTY2wG6xlcGV5vPHlhn889qXojtD-mFLgxEBed6djgI-QmPWKeooTgwBhKv6j_7t6Q==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>.<\/p>\n<p align=\"justify\">Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. AEON does not undertake any duty to update these forward-looking statements.<\/p>\n<p>\n        <strong>Contacts <\/strong>\n      <\/p>\n<p>\n        <strong>Investor Contact: <\/strong><br \/>\n        <br \/>Corey Davis, Ph.D. <br \/>LifeSci Advisors <br \/>+1 212 915 2577 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0hK1ZwlHoWlJTkv9F5HZyAoao588xQhYd1g8cF3QCbuyS83F5bzHWdvqwr-EOjLunZ0rSVtzbCg0GrtgH3oor1jkio-LaWRmX7etWgmXsVBB6CsP0nA-d7sXx8Jq2o7O\" rel=\"nofollow\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a><\/p>\n<p>Source: AEON Biopharma<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTEzMiM2OTA1NzI4IzUwMDA3Mzk5Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OWUyOTJiMzktMGRmNS00MTFhLWEyMzItN2VjYmE1MTdhMGVkLTUwMDA3Mzk5Ny0yMDI1LTA0LTI1LWVu\/tiny\/AEON-Biopharma.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) &#8212; AEON Biopharma, Inc. (\u201cAEON\u201d or the \u201cCompany\u201d) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today it has received notification (the \u201cAcceptance Letter\u201d) from the NYSE American LLC (\u201cNYSE American\u201d) that NYSE American has accepted the Company&#8217;s previously submitted plan (the \u201cPlan\u201d) to regain compliance with NYSE American&#8217;s continued listing standards set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide (the \u201cCompany Guide\u201d) relating to minimum market capitalization and stockholders&#8217; equity. In the Acceptance Letter, NYSE American granted the Company until August 3, 2026 (the \u201cPlan Period\u201d) to regain compliance with the continued listing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-842290","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) &#8212; AEON Biopharma, Inc. (\u201cAEON\u201d or the \u201cCompany\u201d) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today it has received notification (the \u201cAcceptance Letter\u201d) from the NYSE American LLC (\u201cNYSE American\u201d) that NYSE American has accepted the Company&#8217;s previously submitted plan (the \u201cPlan\u201d) to regain compliance with NYSE American&#8217;s continued listing standards set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide (the \u201cCompany Guide\u201d) relating to minimum market capitalization and stockholders&#8217; equity. In the Acceptance Letter, NYSE American granted the Company until August 3, 2026 (the \u201cPlan Period\u201d) to regain compliance with the continued listing &hellip; Continue reading &quot;AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-25T20:19:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTEzMiM2OTA1NzI4IzUwMDA3Mzk5Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance\",\"datePublished\":\"2025-04-25T20:19:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\\\/\"},\"wordCount\":818,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzOTEzMiM2OTA1NzI4IzUwMDA3Mzk5Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\\\/\",\"name\":\"AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzOTEzMiM2OTA1NzI4IzUwMDA3Mzk5Nw==\",\"datePublished\":\"2025-04-25T20:19:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzOTEzMiM2OTA1NzI4IzUwMDA3Mzk5Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzOTEzMiM2OTA1NzI4IzUwMDA3Mzk5Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/","og_locale":"en_US","og_type":"article","og_title":"AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - Market Newsdesk","og_description":"IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) &#8212; AEON Biopharma, Inc. (\u201cAEON\u201d or the \u201cCompany\u201d) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today it has received notification (the \u201cAcceptance Letter\u201d) from the NYSE American LLC (\u201cNYSE American\u201d) that NYSE American has accepted the Company&#8217;s previously submitted plan (the \u201cPlan\u201d) to regain compliance with NYSE American&#8217;s continued listing standards set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide (the \u201cCompany Guide\u201d) relating to minimum market capitalization and stockholders&#8217; equity. In the Acceptance Letter, NYSE American granted the Company until August 3, 2026 (the \u201cPlan Period\u201d) to regain compliance with the continued listing &hellip; Continue reading \"AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-25T20:19:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTEzMiM2OTA1NzI4IzUwMDA3Mzk5Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance","datePublished":"2025-04-25T20:19:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/"},"wordCount":818,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTEzMiM2OTA1NzI4IzUwMDA3Mzk5Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/","name":"AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTEzMiM2OTA1NzI4IzUwMDA3Mzk5Nw==","datePublished":"2025-04-25T20:19:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTEzMiM2OTA1NzI4IzUwMDA3Mzk5Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTEzMiM2OTA1NzI4IzUwMDA3Mzk5Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aeon-biopharma-announces-nyse-american-acceptance-of-plan-to-regain-listing-compliance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/842290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=842290"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/842290\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=842290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=842290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=842290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}